Alpha Tau (DRTS) Medical announced an approval from the U.S. Food and Drug Administration, FDA, of an Investigational Device Exemption IDE, supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients. The IDE supplement allows the Company to include an additional cohort for locally advanced pancreatic cancer patients, and to increase the number of each cohort to 15 patients, for a total of 30 patients across the two cohorts, at up to 10 U.S. clinical trial sites.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau Medical Reports Promising Interim Data and Regulatory Milestones in Cancer Trials
- Alpha Tau shares interim data across multiple clinical trials at R&D Update Day
- Alpha Tau receives IDE from FDA for study evaluating Alpha DaRT, chemo combo
- Alpha Tau announces interim data from pembrolizumab combination trial
- Alpha Tau to Present Groundbreaking Cancer Therapy Data at ASCO Symposium